Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) Given Average Rating of “Moderate Buy” by Analysts

Shares of Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) have earned a consensus rating of “Moderate Buy” from the six research firms that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $5.6667.

Several research firms recently issued reports on IPHA. HC Wainwright lifted their price objective on Innate Pharma from $5.00 to $7.00 and gave the company a “buy” rating in a research note on Monday. Citigroup raised Innate Pharma from a “buy” rating to an “outperform” rating in a report on Tuesday. Weiss Ratings upgraded Innate Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, June 26th. Finally, UBS Group reissued a “buy” rating on shares of Innate Pharma in a report on Tuesday.

Innate Pharma Stock Performance

IPHA opened at $2.22 on Tuesday. The company has a fifty day moving average price of $1.80 and a 200-day moving average price of $1.67. Innate Pharma has a one year low of $1.17 and a one year high of $2.62.

Institutional Investors Weigh In On Innate Pharma

Hedge funds have recently bought and sold shares of the stock. Millennium Management LLC bought a new position in shares of Innate Pharma in the 4th quarter worth $36,000. OLD Mission Capital LLC bought a new stake in shares of Innate Pharma during the 4th quarter worth $50,000. Finally, Jane Street Group LLC bought a new stake in shares of Innate Pharma during the 4th quarter worth $162,000. 0.16% of the stock is currently owned by institutional investors.

About Innate Pharma

Innate Pharma SA is a clinical-stage biotechnology company specializing in the discovery and development of antibody-based therapies that harness the body’s innate immune system to combat cancer. Founded in 1999 and headquartered in Marseille, France, the company pioneers novel monoclonal antibodies designed to activate natural killer cells and macrophages, offering a complementary approach to existing immuno-oncology treatments.

The company’s lead program, monalizumab, targets the NKG2A immune checkpoint receptor and is being developed in collaboration with AstraZeneca.